From Earlier: ChemoCentryx Reports Data for CCX872

by Benzinga Staff
October 2, 2012 9:17 AM | 23 seconds read

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

ChemoCentryx, Inc.(Nasdaq: CCXI) announced today preclinical results for CCX872, the Company'snext-generation, orally bioavailable inhibitor of the chemokine receptor knownas CCR2. The findings showed that treatment with CCX872 improved multipleparameters of renal function in an in vivo model of diabetic nephropathy. Thedata were reported in an oral presentation titled, "CCR2 Inhibition ImprovesRenal Function in Diabetic BTBR ob/ob Mice," at the 48th Annual Meeting of theEuropean Association for the Study of Diabetes (EASD) taking place in Berlin.

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsFDA

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.